

## **Breakthrough Premature Ejaculation Treatment Fortacin™ to Launch in Hong Kong and Macau in Early 2019**

(07 November 2018, Hong Kong) – Regent Pacific Group Limited (“Regent Pacific” or the “Company” and together with its subsidiaries, the “Group”; Hong Kong stock code: 00575), a specialist healthcare and life sciences investment group, has received approval from the Hong Kong Drug Office for the distribution and sale of Fortacin™ in Hong Kong. The Company is in discussions with possible marketing and distribution partners to help facilitate the Hong Kong and Macau roll-out, which is expected in early 2019.

Fortacin™ is the first EU approved prescription treatment for premature ejaculation (“PE”) that does not act on the central nervous system and has been available in key European Union countries from February 2018. The treatment is a topical spray containing low doses of lidocaine and prilocaine that take effect almost immediately upon application, giving users more control without reducing pleasure.

**Jamie Gibson, Chief Executive Officer of Regent Pacific, said,** *“The roll-out of Fortacin™ in Hong Kong and Macau next year will bring an innovative remedy to a condition that is affecting one in every four men globally. The intended launch is expected to deliver a steady stream of recurring cash flow for the Group in the years to come. Our goal is to bring Fortacin™ to men across the world and create substantial returns for our shareholders.”*

The Hong Kong registration will run for an initial period of five years expiring on 18 October 2023 and thereafter for periods of five years at a time on renewal. This registration, together with the import licence already obtained in Macau from the Macau Health Authority, will allow Fortacin™ to be sold, offered for sale and distributed in these regions. The Company is in discussions with possible marketing and distribution partners to help facilitate the Macau and Hong Kong roll-out in early 2019.

Regent Pacific also remains in advanced active discussions with a possible strategic commercial partner for the sale of Fortacin™ in China and for the other remaining key markets of North America, Latin America and the Asia Pacific regions.

**- END -**

### **About Regent Pacific**

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare and life sciences sectors. Its wholly-owned subsidiary, Plethora Solutions Holdings plc, is a specialty pharmaceutical company whose core product Fortacin™ is the first EU approved topical prescription treatment for Premature Ejaculation that does not act on the central nervous system, launched in the UK in November 2016 and in Italy, France, Germany, Portugal and Spain from February 2018 respectively. It is to be launched subsequently in the Czech Republic, Slovakia, Poland, Romania



and Greece, the rest of Europe, Russia, CIS and certain countries of North Africa. The Group has a strong track record of investments and has returned approximately US\$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

**For further information, please contact:**

**Finsbury**

Sheena Shah (Hong Kong)

t : +852 3166 9855

e : [sheena.shah@finsbury.com](mailto:sheena.shah@finsbury.com)

Alastair Hetherington (United Kingdom)

t: +44 20 7251 3801

e: [alastair.hetherington@finsbury.com](mailto:alastair.hetherington@finsbury.com)

Nicole Liu (Hong Kong)

t : +852 3166 9867

e : [nicole.liu@finsbury.com](mailto:nicole.liu@finsbury.com)